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864-2 One-Year Follow-Up of Transendocardial Injection of 
Autologous Bone Marrow Mononuclear Cells for 
Ischemic Cardiomyopathy
Emerson C. Perin, Hans F. Dohmann, Radovan Borojevic, Suzana A. Silva, Andre L. 
Sousa, Guilherme V. Silva, Joao A. Assad, Claudio T. Mesquita, Luciano Belem, Roberto 
Esporcatte, Fernando O. Rangel, Antonio C. Carvalho, Isabel Rossi, William K. Vaughn, 
Hans J. Dohmann, James T. Willerson, Texas Heart Institue, Houston, TX, Pro-Cardiaco 
Hospital, Rio de Janeiro, Brazil
Background: Limited treatment options exist for patients with end-stage ischemic heart
failure (HF) not amenable to revascularization. We evaluated the effect of transendocar-
dial (TE) delivery of Autologous Bone Marrow Mononuclear Cells (ABMMC) in patients
with severe HF.
Methods: Ten patients (mean age 58 ± 11 yrs) were studied. All patients had LV dysfunc-
tion secondary to ischemic cardiomyopathy. Bone marrow (50 ml) was aspirated and
ABMMCs were isolated. TE injections were performed using the Myo-star catheter
(NOGA, Biosense) to target hibernating myocardium guided electromechanical mapping
(EMM). Patients were evaluated by ramp treadmill and Holter monitoring at baseline, 2
months , 6 months and one year. ANOVA was utilized.
Results: Exercise testing showed gradual and continous improvement in METs
(p=0.0005) and VO2max (p=0.002) over time . MET's improved from 4.9 at baseline to
6.7 at 2 months to 7.4 at 6 months up to 7.9 at one year follow-up. There was no differ-
ence in total number of PVC's over the follow-up period. Ramp treadmill findings of
VO2max are presented in figure 1.
Conclusion: In this small number of patients receiving TE injection of ABMMC and fol-
lowed up to one year there was no evidence of significant arrhythmias and there was sus-
tained improvement in exercise capacity. Future studies are needed to further clarify the
role of stem-cell therapy in the treatment of ischemic cardiomyopathy. 
9:00 a.m.
864-3 Transendocardial Autologous Bone Marrow Cell 
Transplantation in Patients With Advanced Ischemic 
Heart Disease: Final Results From a Multi-center 
Feasibility Study
Shmuel Fuchs, Ran Kornowski, Giora Weisz, Lowell F. Satler, Peter C. Smits, Petros 
Okubagzi, Ron Waksman, Neil J. Weissman, Manuel Cerqueira, Alexander Batler, 
Jeffrey W. Moses, Patrick W. Serruys, Martin B. Leon, Stephen E. Epstein, Washington 
Hospital Center, Washington, DC
Background—Experimental and initial clinical data suggest that intra-myocardial injec-
tion of autologous bone marrow (ABM) may improve myocardial perfusion in pts with
obstructive CAD. We therefore conducted a phase I study evaluating the feasibility, safety
and potential efficacy of such a strategy in "no-option" patients with refractory angina and
myocardial ischemia. Methods and Results—Twenty seven pts (58±9 yrs, 22 males, 12
diabetics, 18 with prior MI, 25 post CABG) received evenly distributed 12 transendomyo-
cardial injections (0.2 ml each) of freshly aspirated unfractionated ABM via electrome-
chanical mapping-guided injection catheter. Injected regions encompassed 18.9±6.9% of
total endocardial surface area. Pts were injected with 27±29x106/ml nucleated cells (lym-
phocytes 16.7±7.7%, monocytes fraction 3.9±1.2%, CD34+ 2.2±1.4%, CD34+/CD117+
85.8±12.2% of the total CD34+) directed into pre-defined ischemic myocardium. Proce-
dural success was 100%; mean mapping and injection time was 30±15 and 25±12 min,
respectively. ABM injection was associated with no adverse events. One cultured BM was
found contaminated but without clinical sequelae. At 3-month follow-up, 4 pts were read-
mitted for recurrent chest pain. CCS angina score significantly improved (3.2±0.5 vs.
2.0±0.91, P=0.001) as did frequency of angina (23±22 vs. 40±28, P=0.04) and quality of
life scores (26±16 vs. 44±28, P=0.03).Serial echocardiography showed no deterioration
in segmental or global LV function. Treadmill exercise duration significantly improved
(417±136 vs. 488±206 sec, P=0.05). Stress-induced ischemia within the injected territo-
ries (113 segments) improved (2.2±0.8 vs. 1.7±1.1, P<0.001). At 1-year, clinical
response available in 16 patients was sustained. Complete data will be presented at the
time of the meeting. Conclusions—This feasibility study provides clinical data indicating
safety of catheter-based transendocardial delivery of ABM in patients with advanced
symptomatic ischemic heart disease. The results also suggest potential efficacy, under-
scoring the advisability for further evaluation.
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864-4 Investigating Platelet Activation With Abciximab and 
High-Dose Tirofiban in Patients With Acute Myocardial 
Infarction Undergoing Primary Percutaneous Coronary 
Intervention
Jochem W. van Werkum, Wim B M Gerritsen, Hans C. Kelder, Fred JLM Haas, Maarten-
Jan Suttorp, Egbert T. Bal, Benno JWM Rensing, Sjef MPG Ernst, Jurriën M. ten Berg, 
Sint Antonius Hospital, Nieuwegein, The Netherlands
Background
Glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists have shown to reduce thrombotic complica-
tions in patients undergoing elective percutaneous coronary intervention (PCI). In
patients with acute myocardial infarction (AMI) however, there is only few data on the
amount and duration of platelet activation. In addition, new data suggest that the dose of
tirofiban used in previous studies was too low. The present study investigated platelet
activation in AMI patients undergoing PCI as well as the effects of abciximab and a
higher-dose of tirofiban.
Methods
We prospectively randomised 60 AMI patients to abciximab (N=20; bolus 25 mg/kg, than
12-hours 0,125 mg/kg/min), to high-dose tirofiban (N=20; bolus 25 µg/kg, than 18 hours
0,15 µg/kg/min i.v) or to no addition treatment (N=20). Platelet activation (CD62p and
CD14 positive platelets) and GP IIb/IIIa receptor occupancy (Biotex GP IIb/IIIa receptor
occupancy kit) was measured by flow cytometry at 5 timepoints: before(t=0), immediately
after(t=1), 30 min (t=2), 60 min(t=3) and 120 min (t=4) after PCI. Analysis was done by
repeated measures using ANOVA.
Results
The number of activated platelets in the treated groups were significantly lower than in
the control group (p<0.0001). Abciximab resulted in a significantly higher GP IIb/IIIa
receptor-occupancy than high-dose tirofiban (figure, p<0.0001).
conclusion
Despite an increased high-dose regimen, tirofiban leads to significantly lower platelet
inhibition than abciximab in AMI patients.
9:30 a.m.
864-5 Effects of Prolonged Oral Simvastatin Treatment After 
Coronary Stenting on Neointimal Growth and Plaque 
Progression as Assessed by Intravascular Ultrasound: 
A Randomized Study
Giovanni Amoroso, Anna Sonia Petronio, Barbara Papini, Andrea Micheli, Ugo Limbruno, 
Marco De Carlo, Nicola Ciabatti, Mario Mariani, University of Pisa, Pisa, Italy
BACKGROUND: Statins have proven to reduce adverse events, but not in-stent resteno-
sis (ISR) and plaque progression after coronary stenting.
METHODS: 71 normocholesterolemic consecutive patients with stable angina and a sin-
gle native de-novo lesion suitable for percutaneous intervention, were randomized to sim-
vastatin (S) (20 mg/daily) or placebo (P) 2 weeks before, and continuing for 12 months
after successful coronary stenting. Exclusion criteria were: acute coronary syndromes,
diabetes, ongoing statin treatment. End-points were binary ISR, neointimal growth, and
plaque progression, both at stented and non-stented sites, as assessed by intravascular
ultrasound (IVUS), at 12-month follow-up, major cardiovascular events (MACE).
